The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting accelerating M&A activity in the biotech sector, Germany’s Merck KGaA (MKKGY) announced it will acquire Bio-Techne in an all-cash deal valued at $11.3 billion. The transaction aims to expand Merck’s footprint in life sciences, diagnostics, and bioprocessing, according to an official statement reported by Benzinga.
Bio-Techne specializes in producing reagents and laboratory tools for life science research and diagnostics, a segment experiencing growing global demand. This acquisition follows a series of large deals in the sector, underscoring Merck’s focus on innovation in biotechnology and diagnostic testing.
Sign in to access this content
Sign InShares of MKKGY closed at $31.85 (as of June 24, 2026), per market data. Investors are awaiting further details on the closing timeline and regulatory approvals, as markets continue to assess the impact of major consolidation in the healthcare sector.